摘要
Abstract
Objective To study the clinical value of nitroprusside, shenmai injection and milrinone in treating heart failure in patients with acute myocardial infarction (AMI).Methods Clinical data of 162 patients with heart failure after AMI in our hospital from March was retrospectively analyzed, and were divided into group A (sodium nitroprusside and shenmai injection, 52 cases), group B (milrinone, 54 cases) and group C (basic treatment, 56 cases) according to different treatment.The general information, the condition of clinical medication, the incidence of mortality and adverse reactions, the changes of echocardiographic parameters, vital signs, central venous pressure (CVP) and brain natriuretic peptide(BNP).Results The general information, the incidence of mortality and adverse reactions among the three groups had no significant differences (P>0.05).After treatment, the levels of CVP, HR, CO, LVEDD, LVEF, BNP in three groups were improved than treatment before (P<0.05).The levels of CVP, HR, CO, LVEDD, LVEF, BNP in group B were better than that in group C and group A after treatment (P<0.05).The levels of CVP, HR, CO, LVEF, BNP in group A were better than that in group C after treatment (P<0.05).The values of SBP and DBP before treatment in group A were obviously higher than those after treatment (P<0.05).The values of SBP and DBP before treatment in groups B and C were higher than the treatment after (P>0.05).Conclusion The combination of sodium nitroprusside, shenmai and milrinoneis is safe and effective in treating the patients with heart failure after AMI.The short-time and low-dose administration of milrinoneis is better in improving cardiac function.关键词
硝普钠/参麦注射液/米力农/心力衰竭/急性心肌梗死Key words
sodium nitroprusside/shenmai injection/milrinone/heart failure/acute myocardial infarction分类
医药卫生
